Antibe Therapeutics Stock Probability of Future Pink Sheet Price Finishing Under 0.18
| ATBPF Stock | USD 0.22 0.00 0.00% |
Antibe |
Antibe Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Antibe Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Antibe Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Antibe Therapeutics generated a negative expected return over the last 90 days | |
| Antibe Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (25.06 M) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Antibe Therapeutics has accumulated about 50.19 M in cash with (16.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Timothy J. Arens Sells 7,009 Shares of Surmodics, Inc. Stock |
Antibe Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Antibe Pink Sheet often depends not only on the future outlook of the current and potential Antibe Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Antibe Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.1 M |
Antibe Therapeutics Technical Analysis
Antibe Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Antibe Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Antibe Therapeutics. In general, you should focus on analyzing Antibe Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Antibe Therapeutics Predictive Forecast Models
Antibe Therapeutics' time-series forecasting models is one of many Antibe Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Antibe Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Antibe Therapeutics
Checking the ongoing alerts about Antibe Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Antibe Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Antibe Therapeutics generated a negative expected return over the last 90 days | |
| Antibe Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (25.06 M) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Antibe Therapeutics has accumulated about 50.19 M in cash with (16.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Timothy J. Arens Sells 7,009 Shares of Surmodics, Inc. Stock |
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.